New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
暂无分享,去创建一个
[1] S. Ferrero,et al. How to manage mantle cell lymphoma , 2014, Leukemia.
[2] S. Bates,et al. Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice , 2014, Clinical Cancer Research.
[3] K. Tobinai,et al. Human T-cell Lymphotropic Virus Type I–Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research , 2014, Clinical Cancer Research.
[4] K. Dunleavy,et al. Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype , 2014, Clinical Cancer Research.
[5] G. Salles,et al. Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma? , 2014, Clinical Cancer Research.
[6] F. Cavalli,et al. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas , 2014, Clinical Cancer Research.
[7] F. Cavalli,et al. Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT). , 2014 .
[8] E. Kimby,et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. , 2014, Blood.
[9] M. Jerkeman,et al. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial , 2014, Leukemia & lymphoma.
[10] W. Klapper,et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Quintanilla‐Martinez,et al. Assessing the prognostic impact of immune cell infiltrates in follicular lymphoma , 2014, Haematologica.
[12] A. Rosenwald,et al. The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium , 2014, Haematologica.
[13] J. Leonard,et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity , 2014, Leukemia.
[14] R. Spang,et al. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. , 2013, Blood.
[15] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[16] M. Boccadoro,et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma , 2013, Annals of Hematology.
[17] M. Stauch,et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial , 2013, The Lancet.
[18] N. Schmitz,et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R. Advani,et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] G. Salles,et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. , 2013, Blood.
[21] W. Klapper,et al. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression , 2013, Histopathology.
[22] E. Macintyre,et al. Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study , 2012 .
[23] A. Rosenwald,et al. Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma. , 2012 .
[24] E. Giné,et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.
[25] M. Raffeld,et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index , 2012, Haematologica.
[26] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[27] E. Kimby,et al. Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.
[28] P. Mclaughlin,et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.
[29] L. Staudt,et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. , 2012, Blood.
[30] B. Sander,et al. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. , 2012, Blood.
[31] M. Dreyling,et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. , 2011, Blood.
[32] A. Rosenwald,et al. The complex landscape of genetic alterations in mantle cell lymphoma. , 2011, Seminars in cancer biology.
[33] S. Gaur,et al. Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell lines , 2011, Leukemia & lymphoma.
[34] W. Klapper. Histopathology of mantle cell lymphoma. , 2011, Seminars in hematology.
[35] A. Feldman,et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. , 2011, The Lancet. Oncology.
[36] W. Klapper,et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network , 2010 .
[37] W. Klapper,et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. , 2010, Blood.
[38] E. Kimby,et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). , 2010, Blood.
[39] A. Rosenwald,et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.
[40] B. Sola,et al. The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies , 2009, Haematologica.
[41] M. Eriksson,et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Jeroen van der Laak,et al. Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.
[43] J. Leonard,et al. Outcome of deferred initial therapy in mantle-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. Hoster,et al. Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. Rosenwald,et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] M. Raffeld,et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2 , 2008, Leukemia.
[47] E. Campo,et al. Advances in the understanding of mantle cell lymphoma , 2008, British journal of haematology.
[48] M. Nasr,et al. Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.
[49] W. Klapper,et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.
[50] Adrian Wiestner,et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. , 2007, Blood.
[51] L. Staudt,et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] A Rosenwald,et al. Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) , 2007, Journal of Clinical Pathology.
[53] L. Staudt,et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. , 2006, Blood.
[54] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[55] A. Rosenwald,et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. , 2006, Blood.
[56] G. Brittinger,et al. Repp86: a new prognostic marker in mantle cell lymphoma , 2005, European journal of haematology.
[57] W. Klapper,et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.
[58] Michael L. Wang,et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] W. Klapper,et al. Minichromosome maintenance protein 6, a proliferation marker superior to Ki-67 and independent predictor of survival in patients with mantle cell lymphoma , 2005, British Journal of Cancer.
[60] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] E. Hoster,et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.
[62] P. Korkolopoulou,et al. Topoisomerase IIα as a prognostic factor in mantle cell lymphoma , 2004, Leukemia.
[63] G. Brittinger,et al. Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome , 2004, Leukemia.
[64] F. Bosch,et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. , 2004, The American journal of pathology.
[65] W. Plunkett,et al. Mechanisms of apoptosis induction by nucleoside analogs , 2003, Oncogene.
[66] Nerea Martínez,et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.
[67] T. Barbui,et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). , 2003, Blood.
[68] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[69] K. Franssila,et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. , 2003, European journal of cancer.
[70] K. Franssila,et al. Ki‐67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma , 2002, European journal of haematology.
[71] H. Müller-Hermelink,et al. Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity. , 1997, Blood.
[72] R. Gascoyne,et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. , 1997, Blood.
[73] F. Bosch,et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. , 1996, Blood.
[74] E. Noordijk,et al. Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] T. Lister,et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[77] T. Grogan,et al. Diffuse small cleaved-cell lymphoma: a heterogeneous disease with distinct immunobiologic subsets. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] T. Lister,et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. , 1983, The American journal of pathology.
[79] J. Delabie,et al. Nordic MCL2-3 Trials : Mirna-18B Overexpression Identifies a Mantle Cell Lymphoma Subgroup with Poor Survival and Improves Mipi-B Prediction of Prognosis , 2014 .
[80] Ryan D. Morin,et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. , 2012, Blood.
[81] Y. Sekido,et al. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer , 2010 .
[82] P. Korkolopoulou,et al. Topoisomerase IIalpha as a prognostic factor in mantle cell lymphoma. , 2004, Leukemia.
[83] C. Borrebaeck,et al. Increased expression of Ki-67 in mantle cell lymphoma is associated with de-regulation of several cell cycle regulatory components, as identified by global gene expression analysis. , 2004, Haematologica.